Best Stock for 2013: Mylan
Oftentimes when you bet on a pharma name, you’re betting on one hit-or-miss drug, but not with Mylan. The company has more than 1,000 generic drug products alone, and they’re sold in over 150 countires.
Plus, the stock comes with a lot more to like at both a technical and fundamental level. “Basic technical analysis of Mylan shows a sustained uptrend in the stock, with the stock price returning nearly 20% gains annually for the past five years,” Rick says.
Toss in a low forward P/E, strong renewable cash reserves, stable earnings and strong growth rates, and you have a nice package that just might be exactly what the doctor ordered for 2013.